These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27780690)

  • 21. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management.
    Thorp BC; Badoux X
    Leuk Lymphoma; 2018 Feb; 59(2):311-320. PubMed ID: 28629235
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Rates and Risk of Atrial Arrhythmias in Patients Treated With Ibrutinib Compared With Cytotoxic Chemotherapy.
    Fradley MG; Gliksman M; Emole J; Viganego F; Rhea I; Welter-Frost A; Armanious M; Lee DH; Walko C; Shah B; Chavez JC; McLeod H; Pinilla-Ibarz J; Schabath MB
    Am J Cardiol; 2019 Aug; 124(4):539-544. PubMed ID: 31208701
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety Analysis of Four Randomized Controlled Studies of Ibrutinib in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Mantle Cell Lymphoma.
    O'Brien S; Hillmen P; Coutre S; Barr PM; Fraser G; Tedeschi A; Burger JA; Dilhuydy MS; Hess G; Moreno C; Cramer P; Liu E; Chang S; Vermeulen J; Styles L; Howes A; James DF; Patel K; Graef T; Valentino R
    Clin Lymphoma Myeloma Leuk; 2018 Oct; 18(10):648-657.e15. PubMed ID: 30061088
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma.
    Munir T; Brown JR; O'Brien S; Barrientos JC; Barr PM; Reddy NM; Coutre S; Tam CS; Mulligan SP; Jaeger U; Kipps TJ; Moreno C; Montillo M; Burger JA; Byrd JC; Hillmen P; Dai S; Szoke A; Dean JP; Woyach JA
    Am J Hematol; 2019 Dec; 94(12):1353-1363. PubMed ID: 31512258
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial.
    Sharman JP; Brander DM; Mato AR; Ghosh N; Schuster SJ; Kambhampati S; Burke JM; Lansigan F; Schreeder MT; Lunin SD; Zweibach A; Shtivelband M; Travis PM; Chandler JC; Kolibaba KS; Sportelli P; Miskin HP; Weiss MS; Flinn IW
    Lancet Haematol; 2021 Apr; 8(4):e254-e266. PubMed ID: 33631112
    [TBL] [Abstract][Full Text] [Related]  

  • 27. How I manage ibrutinib intolerance and complications in patients with chronic lymphocytic leukemia.
    Stephens DM; Byrd JC
    Blood; 2019 Mar; 133(12):1298-1307. PubMed ID: 30642919
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and activity of ibrutinib in combination with nivolumab in patients with relapsed non-Hodgkin lymphoma or chronic lymphocytic leukaemia: a phase 1/2a study.
    Younes A; Brody J; Carpio C; Lopez-Guillermo A; Ben-Yehuda D; Ferhanoglu B; Nagler A; Ozcan M; Avivi I; Bosch F; Caballero Barrigón MD; Hellmann A; Kuss B; Ma DDF; Demirkan F; Yağci M; Horowitz NA; Marlton P; Cordoba R; Wrobel T; Buglio D; Streit M; Hodkinson BP; Schaffer M; Alvarez J; Ceulemans R; Balasubramanian S; de Jong J; Wang SS; Fourneau N; Jurczak W
    Lancet Haematol; 2019 Feb; 6(2):e67-e78. PubMed ID: 30642819
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.
    Aw A; Brown JR
    Drugs Aging; 2017 Jul; 34(7):509-527. PubMed ID: 28536906
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ristocetin-induced platelet aggregation for monitoring of bleeding tendency in CLL treated with ibrutinib.
    Kazianka L; Drucker C; Skrabs C; Thomas W; Melchardt T; Struve S; Bergmann M; Staber PB; Porpaczy E; Einberger C; Heinz M; Hauswirth A; Raderer M; Pabinger I; Thalhammer R; Egle A; Wendtner CM; Follows G; Hoermann G; Quehenberger P; Jilma B; Jaeger U
    Leukemia; 2017 May; 31(5):1117-1122. PubMed ID: 27909342
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cardiovascular Risk Associated With Ibrutinib Use in Chronic Lymphocytic Leukemia: A Population-Based Cohort Study.
    Abdel-Qadir H; Sabrie N; Leong D; Pang A; Austin PC; Prica A; Nanthakumar K; Calvillo-Argüelles O; Lee DS; Thavendiranathan P
    J Clin Oncol; 2021 Nov; 39(31):3453-3462. PubMed ID: 34464154
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial Fibrillation and Bleeding in Patients With Chronic Lymphocytic Leukemia Treated with Ibrutinib in the Veterans Health Administration.
    Rasmussen KM; Patil V; Burningham Z; Yong C; Sauer BC; Halwani AS
    Fed Pract; 2020 May; 37(Suppl 2):S44-S49. PubMed ID: 32952387
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Risk of Bleeding Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.
    Wang J; Zhao A; Zhou H; Zhu J; Niu T
    Front Pharmacol; 2020; 11():580622. PubMed ID: 33658926
    [No Abstract]   [Full Text] [Related]  

  • 34. [Ibrutinib-associated atrial fibrillation : A therapeutic challenge].
    Schmitt P; Demoulin R; Poyet R; Capilla E; Rohel G; Pons F; Jégo C; Sidibe S; Prevautel T; Druelle A; Brocq FX; Cellarier GR
    Ann Cardiol Angeiol (Paris); 2022 Nov; 71(5):321-324. PubMed ID: 36115721
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ibrutinib in patients with atrial fibrillation - the challenge of thromboembolic prophylaxis.
    Ciuculete DC; Popescu RA; Dan GA
    Rom J Intern Med; 2021 Sep; 59(3):270-277. PubMed ID: 33913303
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Late onset left ventricular dysfunction and cardiomyopathy induced with ibrutinib.
    Gülsaran SK; Baysal M; Demirci U; Baş V; Kirkizlar HO; Umit E; Demir AM
    J Oncol Pharm Pract; 2020 Mar; 26(2):478-480. PubMed ID: 31142233
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Real-world results of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia: data from 95 consecutive patients treated in a compassionate use program. A study from the Swedish Chronic Lymphocytic Leukemia Group.
    Winqvist M; Asklid A; Andersson PO; Karlsson K; Karlsson C; Lauri B; Lundin J; Mattsson M; Norin S; Sandstedt A; Hansson L; Österborg A
    Haematologica; 2016 Dec; 101(12):1573-1580. PubMed ID: 27198718
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
    Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
    Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Periprocedural Outcomes of Direct Oral Anticoagulants Versus Warfarin in Nonvalvular Atrial Fibrillation.
    Nazha B; Pandya B; Cohen J; Zhang M; Lopes RD; Garcia DA; Sherwood MW; Spyropoulos AC
    Circulation; 2018 Oct; 138(14):1402-1411. PubMed ID: 29794081
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study.
    Ahn IE; Farooqui MZH; Tian X; Valdez J; Sun C; Soto S; Lotter J; Housel S; Stetler-Stevenson M; Yuan CM; Maric I; Calvo KR; Nierman P; Hughes TE; Saba NS; Marti GE; Pittaluga S; Herman SEM; Niemann CU; Pedersen LB; Geisler CH; Childs R; Aue G; Wiestner A
    Blood; 2018 May; 131(21):2357-2366. PubMed ID: 29483101
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.